138.70
0.56%
-0.78
Dexcom Inc stock is currently priced at $138.70, with a 24-hour trading volume of 2.51M.
It has seen a -0.56% decreased in the last 24 hours and a +21.43% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $139.8 pivot point. If it approaches the $137.8 support level, significant changes may occur.
Dexcom Inc Stock (DXCM) Financials Data
Dexcom Inc (DXCM) Revenue 2023
DXCM reported a revenue (TTM) of $3.62 billion for the quarter ending December 31, 2023, a +24.49% rise year-over-year.
Dexcom Inc (DXCM) Net Income 2023
DXCM net income (TTM) was $541.50 million for the quarter ending December 31, 2023, a +58.70% increase year-over-year.
Dexcom Inc (DXCM) Cash Flow 2023
DXCM recorded a free cash flow (TTM) of $511.90 million for the quarter ending December 31, 2023, a +68.00% increase year-over-year.
Dexcom Inc (DXCM) Earnings per Share 2023
DXCM earnings per share (TTM) was $1.31 for the quarter ending December 31, 2023, a +61.73% growth year-over-year.
Dexcom Inc Stock (DXCM) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Dolan Matthew Vincent | EVP Strategy & Corp Dev |
Mar 15 '24 |
Sale |
130.21 |
4,203 |
547,259 |
44,367 |
SAYER KEVIN R | President CEO and Chairman |
Mar 12 '24 |
Sale |
133.36 |
81,007 |
10,802,803 |
333,526 |
Stern Sadie | EVP Chief Human Resources |
Mar 12 '24 |
Sale |
133.61 |
20,321 |
2,715,006 |
80,441 |
Leach Jacob Steven | EVP Chief Operating Officer |
Mar 12 '24 |
Sale |
134.41 |
14,639 |
1,967,638 |
273,913 |
Sylvain Jereme M | EVP Chief Financial Officer |
Mar 12 '24 |
Sale |
134.41 |
11,661 |
1,567,363 |
85,534 |
Brown Michael Jon | EVP Chief Legal Officer |
Mar 12 '24 |
Sale |
134.41 |
8,799 |
1,182,680 |
71,306 |
Dolan Matthew Vincent | EVP Strategy and Corporate |
Mar 12 '24 |
Sale |
134.41 |
6,710 |
901,896 |
48,570 |
Lawver Teri L | EVP Chief Commercial Officer |
Mar 12 '24 |
Sale |
134.41 |
4,764 |
640,333 |
66,641 |
Sylvain Jereme M | EVP Chief Financial Officer |
Feb 20 '24 |
Sale |
116.73 |
3,363 |
392,563 |
71,142 |
SAYER KEVIN R | President, CEO and Chairman |
Jan 16 '24 |
Sale |
123.63 |
37,325 |
4,614,669 |
362,841 |
Dexcom Inc Stock (DXCM) Latest News
DexCom (DXCM) Hits 52-Week High: What's Driving the Stock?
Zacks Investment Research
DexCom (DXCM) Stock Moves -0.12%: What You Should Know
Zacks Investment Research
Has DexCom (DXCM) Outpaced Other Medical Stocks This Year?
Zacks Investment Research
Compelling Reasons to Hold on to UnitedHealth Group (UNH) Stock
Zacks Investment Research
DexCom, Inc. (DXCM) Is a Trending Stock: Facts to Know Before Betting on It
Zacks Investment Research
DexCom (DXCM) Stock Sinks As Market Gains: Here's Why
Zacks Investment Research
About Dexcom Inc
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Cap:
|
Volume (24h):